Core Viewpoint - The innovative drug industry trend remains unchanged, with sufficient adjustments made currently, and it is expected that innovative drugs will rise again after the third quarter reports [1] Group 1: Industry Trends - The CXO sector is performing well, benefiting from potential performance catalysts and high prosperity, with the overseas CXO industry entering a phase of accelerated recovery [1] - There is a clear recovery trend in macro-level BD transactions and mergers and acquisitions, while micro-level new molecular businesses maintain high prosperity [1] - The medical device sector is experiencing a policy turning point, with stock prices, valuations, and allocations at the bottom, and the fundamentals are expected to improve [1] Group 2: Investment Recommendations - It is recommended to focus on innovative drugs, the innovative drug industry chain (export-oriented CXO), and medical devices as the main lines for medium to long-term investment [1] Group 3: ETF Performance - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking 30 representative quality companies in the Shanghai Stock Exchange Sci-Tech Innovation Drug Index, primarily featuring high-growth biotech [1] - Since the "924 market" last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovative Drug Index, with respective gains of 117.04% and 109.62% during the market rebound period from September 24, 2024, to September 30, 2025 [1] - The Sci-Tech Innovation Drug Index may help better share the elasticity of the Sci-Tech Innovation Board when market risk appetite rebounds [1]

Group 1: Fund Performance and Holdings - The performance of several high-performing funds has been highlighted, with notable increases in their asset sizes, such as Zhonghang Opportunity Navigator reaching 13.23 billion yuan, a nearly 12-fold increase from the previous quarter [2][4] - Yongying Medical Innovation Select reported a 157.28% growth in size, reaching 7.83 billion yuan by the end of Q3 [2][6] - The top holdings of these funds include significant stocks in the AI computing and innovative pharmaceutical sectors, with many stocks experiencing substantial price increases this year [3][6] Group 2: Investment Focus Areas - Zhonghang Opportunity Navigator focuses on the AI computing industry, with a stock position of 88.56% and significant increases in holdings of key stocks like Huadian Co., which saw a 669.13% increase in shares held [3][4] - Yongying Medical Innovation Select emphasizes innovative pharmaceuticals, with top holdings exceeding 700 million yuan, and several stocks seeing their holdings double compared to the previous quarter [6][7] - Penghua Carbon Neutral Theme Fund is investing in manufacturing, new energy, and new technologies, achieving a profit of 3.33 billion yuan in Q3 [9][10] Group 3: Market Outlook - The long-term growth potential of AI computing is emphasized, with expectations for a technology cycle lasting at least 5 to 10 years, particularly in robotics and new industrial applications [11][12] - The innovative pharmaceutical sector is viewed as a strong investment theme, with potential for significant returns as domestic innovations gain global competitiveness [8][6] - The overall market outlook remains optimistic despite potential pressures from trade disputes, with expectations for stable economic performance in the fourth quarter [15]

Investment Rating - The report rates the pharmaceutical industry as "Positive" [1][33] Core Viewpoints - The source of innovation in the pharmaceutical industry is improving, and short-term fluctuations do not change long-term value. The ESMO 2025 conference highlighted 23 "Late-Breaking Abstracts" led by Chinese scholars, with 3 significant results presented at the highest academic level, indicating China's growing position in global pharmaceutical innovation [5][26] - Domestic innovative drugs are showing competitive clinical data, with several products demonstrating global competitiveness. For instance, the sac-TMT from Kelun Biotech is expected to be a strong competitor for EGFR mutation NSCLC after EGFR-TKI resistance [5][6] - Investment suggestions focus on shifting attention from "expectations" to "realization" of clinical data and commercialization. Key directions include companies with validated R&D and commercialization capabilities, those entering performance release periods, and those with excellent clinical data pipelines [5][27] Summary by Sections Section 1: Kelun Biotech - The sac-TMT is expected to be a strong competitor for EGFR mutation NSCLC after EGFR-TKI treatment failure, with significant clinical data presented at ESMO 2025 [6][8] Section 2: Kangfang Biotech - The HARMONi-6 study results met expectations, showing significant PFS benefits compared to the control group, with ongoing overseas clinical research updates anticipated [9][10] Section 3: Basestone Pharmaceuticals - The CS2009's efficacy and safety have been preliminarily validated, showing promise as a next-generation I-O therapy competitor [12][14] Section 4: Shouyao Holdings - The SY-5007 demonstrated significant efficacy advantages in RET fusion-positive NSCLC patients, with a low treatment-related discontinuation rate [16][18] Section 5: Jinfang Pharmaceuticals - The GFH375 showed promising efficacy in treating KRAS G12D mutation pancreatic cancer, with a notable objective response rate [19][21] Section 6: Aosaikang - The ASKB589 combined with chemotherapy and PD-1 inhibitors showed significant survival benefits in advanced gastric cancer patients [23][25]

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing a recovery, with several stocks such as Hengrui Medicine, Junshi Biosciences, and others rising over 3% [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) showed positive movement, with trading volume exceeding 260 million yuan in less than half a day [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 108.14% year-to-date, outperforming other innovative drug indices [6][7]. Group 2: Technical Analysis - The ETF's index is currently testing a critical half-year line, with future movements dependent on whether it breaks below or stabilizes above this line [3]. - If the index stabilizes and moves upward, it may signal a stop in the downward trend, presenting a higher probability for entry [3]. Group 3: Fundamental Analysis - The market is shifting from a broad-based rally to a focus on quality factors, emphasizing the importance of innovative drugs with strong clinical data and commercialization capabilities [5]. - The ETF exclusively tracks innovative drug companies, with over 70% of its holdings in large-cap leaders, indicating a strong focus on high-quality investments [5][6]. Group 4: ETF Details - The ETF has a total fund size of 1.806 billion yuan and has the highest liquidity among similar indices, with an average daily trading volume of 493 million yuan since its inception [7].

医药行业边际改善，布局 Q3 业绩超预期与高景气方向 [Table_Industry] 医药生物行业周报 [Table_ReportTime] 2025 年 10 月 27 日 证券研究报告 行业研究 [Table_ReportType] 行业周报 医药生物 医药生物 投资评级 看好 上次评级 看好 [Table_A 唐爱金 uthor 医药首席分析师 ] 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药联席首席分析师 执业编号：S1500524120003 邮 箱：hexin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 赵丹 医药行业分析师 执业编号：S1500524120002 邮 箱：zhaodan@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大 ...

Core Viewpoint - The Hong Kong Innovative Drug 50 ETF (513780) has shown significant growth, with a 44.49% increase over the past six months, indicating strong performance in the innovative pharmaceutical sector [1][2] Group 1: ETF Performance - As of October 27, 2025, the Hong Kong Innovative Drug 50 ETF rose by 1.16%, reaching a peak increase of over 2% during the trading session [1] - The ETF ranks first among similar index funds in terms of growth, reflecting robust investor interest in innovative pharmaceuticals [1] Group 2: Company Earnings - WuXi AppTec reported a revenue of 32.857 billion yuan for the first three quarters of 2025, marking an 18.61% year-on-year increase, with a net profit of 12.076 billion yuan, up 84.84% [1] - In Q3 2025, the company achieved a revenue of 12.057 billion yuan, a 15.26% increase year-on-year, and a net profit of 3.515 billion yuan, reflecting a 53.27% growth [1] Group 3: Market Trends and Insights - Everbright Securities noted that the Federal Reserve has initiated a rate-cutting cycle, which is favorable for the innovative pharmaceutical sector, particularly for innovative drugs and devices [1] - The current investment focus in the pharmaceutical industry should emphasize clinical value, addressing patient needs, with both domestic and international policies providing higher premiums for clinical value [1] - The reduction in interest rates is expected to improve the financing environment for pharmaceutical companies, particularly benefiting biotech firms and increasing demand for CXO services, positively impacting new orders and performance growth [1] Group 4: Industry Dynamics - The innovative drug market is transitioning from a broad rally to a focus on "quality factors," where only leading innovative drugs with strong clinical data and commercialization capabilities will achieve financial success [2] - The Hong Kong Innovative Drug 50 ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes leading companies like WuXi Biologics, Innovent Biologics, and BeiGene, with nearly 90% weight in biopharmaceuticals and chemical drugs [2] - The ETF allows T+0 trading and has established off-market connection funds for investors to maintain interest in the high-volatility Hong Kong innovative drug sector [2]

Core Viewpoint - The innovation drug sector in China is experiencing significant growth, driven by policy support, innovation upgrades, and normalization of overseas business development, indicating a period of high prosperity for the industry [5]. Group 1: Market Performance - As of October 27, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Innovation Drug Index rose by 2.50%, with notable increases in constituent stocks such as Ailis (up 5.76%) and ZhiXiang JinTai (up 5.63%) [1]. - The Huatai-PineBridge Innovation Drug ETF (589120) increased by 2.67%, with a latest price of 0.89 yuan, and has seen a cumulative increase of 1.06% since the beginning of October [1]. - The ETF recorded a turnover rate of 4.12% and a trading volume of 15.2063 million yuan, with an average daily trading volume of 24.6571 million yuan over the past year [1]. Group 2: Financial Performance - WuXi AppTec reported a net profit of 3.515 billion yuan for Q3 2025, a year-on-year increase of 53.27%, and a total net profit of 12.076 billion yuan for the first three quarters, up 84.84% year-on-year [3]. - The growth in profits is attributed to the company's focus on the CRDMO business model, increased operational efficiency, and gains from the sale of shares in WuXi XDC Cayman Inc. [3]. Group 3: Industry Developments - The 2025 European Society for Medical Oncology (ESMO) annual meeting showcased significant breakthroughs in Chinese innovative drug research, with multiple clinical data points reaching international leading levels [4]. - Notable presentations included CanSino Biologics' results on the efficacy of Ivosidenib in advanced squamous non-small cell lung cancer and Rongchang Biologics' RC48-C016 study in HER2+ urothelial carcinoma, which achieved significant benefits in progression-free survival (PFS) and overall survival (OS) [4]. - The Federal Reserve's initiation of a rate-cutting cycle is expected to benefit innovative assets, particularly in the pharmaceutical sector, as historical trends show that innovative assets tend to outperform during such periods [4].

Core Insights - The Federal Reserve has initiated a rate-cutting cycle, which is favorable for the pharmaceutical and biotechnology sectors, particularly for innovative drugs and devices [1] - By September 2025, further rate cuts are expected, leading to a more accommodative macro environment and an increase in valuation premiums for innovative assets [1] Industry Focus - Investment in the pharmaceutical industry should concentrate on the intrinsic logic of clinical value, which addresses the needs of patients and healthcare providers, as both domestic and international policies are assigning higher premiums to clinical value [1] - The reduction in interest rates will improve the financing environment for pharmaceutical companies, particularly benefiting biotech firms, which will increase R&D investments and positively impact the demand for CXO services [1] Market Performance - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which saw a daily fluctuation of 20%. This index includes listed companies involved in biomedicine, medical devices, and related services, reflecting the overall performance of the pharmaceutical sector on the Growth Enterprise Market [1]

Group 1 - The pharmaceutical sector opened high on October 27, with the Hong Kong pharmaceutical ETF (159718.SZ) rising by 1.02% [1] - Notable stocks such as WuXi AppTec (药明康德) reported a revenue of RMB 32.86 billion for the first three quarters of 2025, marking an 18.6% year-on-year increase, and a net profit of RMB 12.076 billion, up 84.84% [1] - WuXi AppTec expects its revenue for the full year to be adjusted from RMB 42.5-43.5 billion to RMB 43.5-44 billion, with a focus on its CRDMO core business [1] Group 2 - The CXO sector continues to show strong performance, with companies like WuXi AppTec, Boteng Co., and MEDPACE exceeding expectations [2] - The innovative drug industry chain fundamentals remain positive, supported by recent financing data and the sustainable trend of innovative drugs going global [2] - The Hong Kong pharmaceutical ETF (159718.SZ) offers a balanced composition, including innovative drugs, CXO, internet healthcare, and innovative medical devices, making it a convenient investment tool for the sector [2]

Group 1: Pharmaceutical Sector Overview - The 2025 Jiangxi Pharmaceutical Development Conference held on October 25 in Ganzhou signed 16 key pharmaceutical projects covering various fields including innovative drugs, traditional Chinese medicine, pet medicine, medical devices, and pharmaceutical innovation platforms [1] - Galaxy Securities indicates that the pharmaceutical sector has undergone a significant structural repair trend after a prolonged valuation adjustment, with public fund holdings still below historical averages. In 2025, under the policy backdrop supporting commercial insurance development, there is potential for marginal improvement in payment [1] - Continuous optimism for pharmaceutical innovation is noted, with expectations that the second half of the year will see ongoing business development (BD) for innovative drugs, and a global trend of central banks lowering interest rates may further enhance valuations [1] Group 2: Retail and Distribution Insights - CITIC Securities highlights that the pharmacy industry is stabilizing, with leading pharmacies operating steadily and valuations at historical lows. Short-term focus includes demand recovery, industry concentration increase, and outpatient coordination policy increments [2] - In the distribution sector, leading companies are stabilizing, with future attention on improving receivables and long-term growth expectations driven by the "14th Five-Year Plan" [2] - The traditional Chinese medicine sector is experiencing easing pressure from base effects, with channel adjustments accelerating. Demand is expected to recover by the end of the year, while both sector valuations and institutional holdings remain low [2]